These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1618 related items for PubMed ID: 19288493

  • 1. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I, Pollak Y, Broneshter R, Iancu TC.
    FEBS J; 2011 Sep 15; 278(18):3494-507. PubMed ID: 21790999
    [Abstract] [Full Text] [Related]

  • 4. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 15; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 5. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
    Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X.
    Eur J Cancer; 2010 Mar 15; 46(4):836-50. PubMed ID: 20071162
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.
    Lu X, Tang X, Guo W, Ren T, Zhao H.
    J Surg Oncol; 2010 Dec 01; 102(7):821-6. PubMed ID: 20812347
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L, Trail PA, Taylor I, Wilhelm SM.
    Methods Enzymol; 2006 Dec 01; 407():597-612. PubMed ID: 16757355
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S, Lee SH, Dean NM, McMahon M.
    Cancer Res; 2005 Jun 01; 65(11):4870-80. PubMed ID: 15930308
    [Abstract] [Full Text] [Related]

  • 9. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R, Piperdi S, Gorlick R.
    Clin Cancer Res; 2008 Oct 15; 14(20):6396-404. PubMed ID: 18927278
    [Abstract] [Full Text] [Related]

  • 10. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 15; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 11. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
    Wang J, Zhao Y, Kauss MA, Spindel S, Lian H.
    Eur J Cell Biol; 2009 Feb 15; 88(2):103-15. PubMed ID: 19058874
    [Abstract] [Full Text] [Related]

  • 12. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
    Lee M.
    Biochem Biophys Res Commun; 2006 Nov 17; 350(2):450-6. PubMed ID: 17010316
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Wei G, Wang M, Carr BI.
    J Cell Physiol; 2010 Jul 17; 224(1):112-9. PubMed ID: 20301194
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.
    Cancer Res; 2009 Aug 15; 69(16):6515-21. PubMed ID: 19638574
    [Abstract] [Full Text] [Related]

  • 15. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
    Chapuy B, Schuelper N, Panse M, Dohm A, Hand E, Schroers R, Truemper L, Wulf GG.
    Br J Haematol; 2011 Feb 15; 152(4):401-12. PubMed ID: 21689083
    [Abstract] [Full Text] [Related]

  • 16. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
    Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R, Aoudjit F.
    Mol Cancer Res; 2008 Jan 15; 6(1):42-52. PubMed ID: 18234961
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
    Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, Gu Y, Shu Y, Shen Y, Sun Y, Xu Q.
    Anticancer Drugs; 2011 Jan 15; 22(1):79-88. PubMed ID: 20881478
    [Abstract] [Full Text] [Related]

  • 18. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 15; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 19. Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells.
    Motomura W, Tanno S, Takahashi N, Nagamine M, Fukuda M, Kohgo Y, Okumura T.
    Biochem Biophys Res Commun; 2005 Jun 24; 332(1):89-94. PubMed ID: 15896303
    [Abstract] [Full Text] [Related]

  • 20. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    Jane EP, Premkumar DR, Pollack IF.
    J Pharmacol Exp Ther; 2006 Dec 24; 319(3):1070-80. PubMed ID: 16959960
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 81.